Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 25, 2023

Safety and Efficacy of Combined Therapy With Selinexor and Eribulin in Patients With Advanced Solid Tumors and TNBC

Cancer

 

Additional Info

Cancer
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer
Cancer 2023 Jul 15;129(14)2201-2213, BE Nelson, S Saleem, S Damodaran, N Somaiah, S Piha-Paul, JA Moore, B Yilmaz, D Ogbonna, DD Karp, E Dumbrava, AM Tsimberidou, DS Hong, J Rodon Ahnert, DR Milton, X Zheng, DJ Booser, NK Ibrahim, AP Conley, P Bhosale, CM Rojas Hernandez, D Tripathy, A Naing, F Meric-Bernstam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading